{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A361", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004086, "timestamp_received": "2026-09-25T00:13:59.339910+00:00Z", "timestamp_returned": "2026-09-25T00:13:59.343996+00:00Z", "trace_id": "df2efaca-40b9-4fab-ad18-1ee1593929d2" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:iclusig:0:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The product label notes that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). This indication is based on PhALLCON (NCT03589326), a randomized, active-controlled, multicenter, open-label trial in which chemotherapy regimens were: vincristine and dexamethasone (induction, cycles 1 to 3); methotrexate and cytarabine (consolidation, cycles 4 to 9, alternating methotrexate and cytarabine); and vincristine and prednisone (maintenance, cycles 10 to 20).", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2024-03-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2024-03-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:iclusig", "type": "Document", "documentType": "Regulatory approval", "name": "Iclusig (ponatinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Takeda Pharmaceuticals America, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Iclusig", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ponatinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2012-12-14", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 203469, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:361", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:ALL", "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL" ] } }, "objectTherapeutic": { "id": "txgrp:75", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C408", "conceptType": "Therapy", "name": "Cytarabine", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:3041", "code": "3041", "name": "cytarabine", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3041" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1311078", "code": "1311078", "name": "cytarabine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1311078" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:387511003", "code": "387511003", "name": "Cytarabine", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387511003&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4306038", "code": "4306038", "name": "Cytarabine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4306038" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "DNA Polymerase inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408" ] } }, { "id": "tx:ncit:C422", "conceptType": "Therapy", "name": "Dexamethasone", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:3264", "code": "3264", "name": "dexamethasone", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3264" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1518254", "code": "1518254", "name": "dexamethasone", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1518254" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:372584003", "code": "372584003", "name": "Dexamethasone", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=372584003&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4156734", "code": "4156734", "name": "Dexamethasone", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4156734" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Corticosteroid" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C422", "code": "C422", "name": "Dexamethasone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C422" ] } }, { "id": "tx:ncit:C642", "conceptType": "Therapy", "name": "Methotrexate", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:6851", "code": "6851", "name": "methotrexate", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=6851" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1305058", "code": "1305058", "name": "methotrexate", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1305058" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:387381009", "code": "387381009", "name": "Methotrexate", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387381009&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4301206", "code": "4301206", "name": "Methotrexate", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4301206" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Antifolate" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C642", "code": "C642", "name": "Methotrexate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C642" ] } }, { "id": "tx:ncit:C95777", "conceptType": "Therapy", "name": "Ponatinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1364347", "code": "1364347", "name": "ponatinib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1364347" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45771379", "code": "45771379", "name": "Ponatinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45771379" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:703796003", "code": "703796003", "name": "Ponatinib", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=703796003&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43013182", "code": "43013182", "name": "ponatinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43013182" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "BCR-ABL inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C95777", "code": "C95777", "name": "Ponatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777" ] } }, { "id": "tx:ncit:C770", "conceptType": "Therapy", "name": "Prednisone", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:8640", "code": "8640", "name": "prednisone", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=8640" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1551099", "code": "1551099", "name": "prednisone", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1551099" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:116602009", "code": "116602009", "name": "Prednisone", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=116602009&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4023242", "code": "4023242", "name": "Prednisone", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4023242" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Corticosteroid" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C770", "code": "C770", "name": "Prednisone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770" ] } }, { "id": "tx:ncit:C933", "conceptType": "Therapy", "name": "Vincristine", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:11202", "code": "11202", "name": "vincristine", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=11202" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1308290", "code": "1308290", "name": "vincristine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1308290" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:387126006", "code": "387126006", "name": "Vincristine", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387126006&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4304296", "code": "4304296", "name": "Vincristine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4304296" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Vinca alkaloid chemotherapy" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C933", "code": "C933", "name": "Vincristine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:12", "present": true, "subject": { "id": "bmkr:12", "type": "CategoricalVariant", "name": "BCR::ABL1", "constraints": [ { "type": "AdjacencyConstraint", "orderKnown": true, "adjoinedElements": [ { "id": "gene:hgnc:1014", "conceptType": "Gene", "name": "BCR", "primaryCoding": { "id": "coding:hgnc:1014", "code": "HGNC:1014", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000186716", "code": "ENSG00000186716", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000186716" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:613", "code": "613", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/613" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004327.4", "code": "NM_004327.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4" ] } } ] }, { "id": "gene:hgnc:76", "conceptType": "Gene", "name": "ABL1", "primaryCoding": { "id": "coding:hgnc:76", "code": "HGNC:76", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000097007", "code": "ENSG00000097007", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000097007" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:25", "code": "25", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/25" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005157.6", "code": "NM_005157.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6" ] } } ] } ] } ], "extensions": [ { "name": "biomarker_type", "value": "Gene fusion" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:iclusig:0", "type": "Indication", "description": "ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2024-03-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2024-03-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:iclusig", "type": "Document", "documentType": "Regulatory approval", "name": "Iclusig (ponatinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Takeda Pharmaceuticals America, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Iclusig", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ponatinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2012-12-14", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 203469, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }